Pharmacologic management of comorbid post-traumatic stress disorder and addictions: Pharmacology of PTSD and SUD
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Post-traumatic Stress Disorder (PTSD) and substance use disorders (SUD) frequently co-occur, and their combination can increase poor health outcomes as well as mortality. METHODS: Using PUBMED and the list of references from key publications, this review article covered the epidemiology, neurobiology and pharmacotherapy of PTSD with comorbid alcohol, opiate, and cannabis use disorders. These SUD represent two with and one without FDA approved pharmacotherapies. RESULTS: SUD is two to three times more likely among individuals with lifetime PTSD, and suicide, which is made more likely by both of these disorders, appears to be additively increased by having this comorbidity of SUD and PTSD. The shared neurobiological features of these two illnesses include amygdalar hyperactivity with hippocampal, medial prefrontal and anterior cingulate cortex dysfunction. Medications for comorbid PTSD and SUD include the PTSD treatment sertraline, often used in combination with anticonvulsants, antipsychotics, and adrenergic blockers. When PTSD is comorbid with alcohol use disorder (AUD), naltrexone, acamprosate or disulfiram may be combined with PTSD treatments. Disulfiram alone may treat both PTSD and AUD. For PTSD combined with opiate use disorder methadone or buprenorphine are most commonly used with sertraline. Marijuana use has been considered by some to be a treatment for PTSD, but no FDA treatment for this addiction is approved. Pregabalin and D-cycloserine are two innovations in pharmacotherapy for PTSD and SUD. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Comorbid PTSD and SUD amplifies their lethality and treatment complexity. Although they share important neurobiology, these patients uncommonly respond to a single pharmacotherapy such as sertraline or disulfiram and more typically require medication combinations and consideration of the specific type of SUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Posttraumatic stress disorder among substance users from the general population
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.5.664 · Cited by 479
Morphine use after combat injury in Iraq and post-traumatic stress disorder
Holbrook, T. L., Galarneau, M. R., Dye, J. L., Quinn, K., & Dougherty, A. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903326 · Cited by 429
Leeies, M., Pagura, J., Sareen, J., & Bolton, J. M. (2010) · Depression and Anxiety · doi:10.1002/da.20677 · Cited by 300
Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms
Budney, A. J., Vandrey, R. G., Hughes, J. R., Moore, B. A., & Bahrenburg, B. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.014 · Cited by 180
Genetics of PTSD: fear conditioning as a model for future research
Amstadter, A. B., Nugent, N. R., & Koenen, K. C. (2009) · Psychiatric Annals · doi:10.3928/00485713-20090526-01 · Cited by 150
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., & Cohen, T. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003061 · Cited by 134
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Cornelius, J. R., Bukstein, O. G., Douaihy, A. B., Clark, D. B., Chung, T. A., Daley, D. C., Wood, D. S., & Brown, S. J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.05.010 · Cited by 105
PTSD contributes to teen and young adult cannabis use disorders
Cornelius, J. R., Kirisci, L., Reynolds, M., Clark, D. B., Hayes, J., & Tarter, R. (2010) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.09.007 · Cited by 80
Suicidal ideation and risk factors in primary care patients with anxiety disorders
Bomyea, J., Lang, A. J., Craske, M. G., Chavira, D., Sherbourne, C. D., Rose, R. D., Golinelli, D., Campbell-Sills, L., Welch, S. S., Sullivan, G., et al. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.03.017 · Cited by 47
Cited by
Hawn, S. E., Cusack, S. E., & Amstadter, A. B. (2020) · Journal of Traumatic Stress · doi:10.1002/jts.22521 · Cited by 286
Hassan, A. N., Le Foll, B., Imtiaz, S., & Rehm, J. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.07.012 · Cited by 80
Post-traumatic stress disorder and opioid use disorder: a narrative review of conceptual models
Danovitch, I. (2016) · Journal of Addictive Diseases · doi:10.1080/10550887.2016.1168212 · Cited by 55
Brewerton, T. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1149433 · Cited by 46
Cruz, B., Vozella, V., Carper, B. A., Xu, J. C., Kirson, D., Hirsch, S., Nolen, T., Bradley, L., Fain, K., Crawford, M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01497-w · Cited by 25
Self-citation
Metadata
- Authors
- Shorter, D., Hsieh, J., & Kosten, T. R.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2015-11-20
- Volume
- 24
- Issue
- 8
- Pages
- 705-712
- ISSN
- 1055-0496 (ISSN-L)
- OpenAlex
- W2179834133
- Cited by
- 65
- References
- 12
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.